Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

InMed Pharmaceuticals Announces Additional IntegraSyn Patent Filing

Author: Benzinga Newsdesk | September 22, 2020 07:32am

VANCOUVER, BC, Sept. 22, 2020 /PRNewswire/ -InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN) (OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol("CBN"), today announced the filing of a patent application as part of a growing portfolio of intellectual property related to the IntegraSyn™manufacturing approach for producing low-cost, pharmaceutical-grade cannabinoids.

Posted In: IMLFF TSX:IN